Last reviewed · How we verify
MEDI7247
At a glance
| Generic name | MEDI7247 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (PHASE1)
- A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI7247 CI brief — competitive landscape report
- MEDI7247 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI